Ae Ree Kim
Korea University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ae Ree Kim.
Acta Oncologica | 2013
Jung Sun Kim; Eun Joo Kang; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae Ree Kim; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Abstract Background. It has long been recognized that some human breast cancers are hormone dependent. Preeclampsia is a syndrome of pregnancy defined by the onset of hypertension and proteinuria and characterized by dysfunction of the maternal endothelium. Many hormonal changes occur with preeclampsia, and we hypothesize that these changes may influence the risk of maternal breast cancer. We also analyzed the relation between pregnancy-induced hypertension (PIH) and maternal risk of breast cancer. Methods. Among 13 relevant publications about preeclampsia and six relevant publications about PIH, some studies find preeclampsia associated with a lower risk of breast cancer, but others did not. Therefore, these results are inconclusive. We conducted meta-analysis to evaluate more precisely the relationship between preeclampsia, PIH and maternal risk of breast cancer. Results. The pooled estimate of the hazard ratio (HR) associated with preeclampsia was 0.86 (95% CI 0.73–1.01), and that associated with PIH was 0.83 (0.66–1.06), both based on the random effects model. Conclusion. Some suggestive but not entirely consistent nor conclusive evidence was found on the association between the history of preeclampsia or PIH with the subsequent risk of breast cancer.
Investigational New Drugs | 2011
Jae Bok Lee; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae Ree Kim; Eun Sook Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
SummaryAlthough various new agents have been developed for the treatment of patients with metastatic breast cancer (MBC), overall survival rates have changed little in the last half century. We conducted meta-analysis to verify the clinical efficacy of bevacizumab for the salvage treatment of MBC. Event-based hazard ratios (HR) with 95% confidence intervals (95% CIs) were derived, and a test of heterogeneity was applied. Four studies, with a total of 2,860 patients, met the inclusion criteria for analysis. The pooled results of clinical efficacies were: HR for progression free survival 0.69 (95% CI, 0.58–0.81, z = 4.54, P <0.001); HR for overall survival 0.92 (95% CI, 0.82–1.03, z =1.44, P = 0.15); and HR for the clinical objective response rate 1.53 (95% CI, 1.37–1.71, z = 7.37, P < 0.001). In terms of overall survival, subgroup analysis demonstrated statistically significant improvement for the bevacizumab combination in the initial therapy subgroup (HR, 0.878; 95% CI, 0.771–0.999, z = 1.98, P = 0.048). Hypertension and proteinura were more common in the bevacizumab combination arm; however, these toxicities were managed with therapy. In conclusion, meta-analysis suggested benefits of a carefully managed bevacizumab-containing salvage regimen for patients with histologically or cytologically confirmed Her-2 negative MBC who have not received previous cytotoxic therapy. This treatment could improve both progression free survival and overall survival rates.
Cancer Genetics and Cytogenetics | 2010
Dae Sik Yang; Hwa Jung Sung; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Ae Ree Kim; Eun Sook Lee; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Published studies on the association between the progesterone receptor gene +331 G/A polymorphism and breast cancer risk are inconclusive, and meta-analysis is required to verify the association. Six studies, including a total of 6,849 cases and 6,589 controls, were subjected to meta-analysis. When all eligible subjects were pooled for meta-analysis, the AG + AA variant genotype was not associated with a significantly elevated breast cancer risk [odds ratio (OR) = 1.11; 95% confidence interval (95%CI) = 0.99-1.24; P = 0.071]. However, subgroup analysis revealed that the AG + AA variant genotype was associated with an increased risk of breast cancer in American (OR = 1.32; 95%CI = 1.10-1.58; P = 0.003), but not in European or Australian. We could carefully suggest that the progesterone receptor promoter +331 G/A variant polymorphism might increase breast cancer risk, and this effect appeared to be more prominent in Americans than in Europeans and Australians.
Journal of Cancer Research and Therapeutics | 2018
Hyun Goo Kim; Sang Uk Woo; Hoon Kim; Gil Soo Son; Jae Bok Lee; Jeong Won Bae; Ok Hee Woo; Dae Sik Yang; Jae Hong Seo; Ae Ree Kim
Background: Insulin receptor substrate 1 (IRS-1) has been known to be an associated factor with breast cancer progression. However, there has been little study with respect to the relationship between the expression of IRS-1 and breast cancer prognosis in clinical practice. In this study, we evaluated the impact of the estrogen receptor (ER) and IRS-1 on the recurrence and survival of breast cancer patients. Methods: We analyzed the pathologic finding of 376 tissue samples from breast cancer patients who received proper treatment between January 1990 and December 2006 using the tissue microarray. We measured the expression of ER and IRS-1 by immunohistochemistry staining and analyzed the difference of recurrence and survival rate in each subgroup of ER and IRS-1. Results: Our results show that there is a significant difference of disease-free survival (DFS) according to ER and IRS-1 subgroups with both univariate and multivariate analyses. Specifically, ER-positive and IRS-1-positive breast cancer samples showed improved DFS compared to ER-positive and IRS-1-negative breast cancer (adjusted hazard ratio: 2.17; 95% confidence interval: 1.15–4.09; P = 0.01). There was a difference of overall survival according to ER and IRS-1 subgroups by univariate analysis (P = 0.01), but not by multivariate analysis (P = 0.36). Conclusion: ER and IRS-1 subgroups appear to be critical factors for the prediction of breast cancer recurrence. In particular, we suggest that the patients who have ER-positive and IRS-1-negative breast cancer undergo more aggressive treatment because they have poorer prognoses.
Breast Cancer Research and Treatment | 2011
Dae Sik Yang; Kyong Hwa Park; Ok Hee Woo; Sang Uk Woo; Ae Ree Kim; Eun Sook Lee; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Cancer Chemotherapy and Pharmacology | 2006
Jae Hong Seo; Sang Cheul Oh; Cheul Won Choi; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Ae Ree Kim; Jae Bok Lee; Bum Hwan Koo
Investigational New Drugs | 2011
Hee Yeon Seo; Hyun Joo Lee; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae Ree Kim; Jae Bok Lee; Eun Sook Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Breast Cancer Research and Treatment | 2010
Sang Uk Woo; Kyong Hwa Park; Ok Hee Woo; Dae Sik Yang; Ae Ree Kim; Eun Sook Lee; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Tumor Biology | 2014
Eun Joo Kang; Hoiseon Jung; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae Ree Kim; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo
Breast Cancer Research and Treatment | 2012
Hye Sook Kim; Ok Hee Woo; Kyong Hwa Park; Sang Uk Woo; Dae Sik Yang; Ae Ree Kim; Eun Sook Lee; Jae Bok Lee; Yeul Hong Kim; Jun Suk Kim; Jae Hong Seo